In this GEN webinar, our expert panelists will introduce bioSensAll™, an enhanced bystander bioluminescenceresonance energy transfer (ebBRET)-based .. Read more biosensor technology and its applications to interrogateRTK biology and expand current RTK drug discovery efforts. Dysregulated RTK activity can affect many cellular functions, often culminating in cancer, making RTKs prime targets for new anti-cancer agents. Furthermore, mutations in RTKs may alter receptor activity or prevent drug binding as a consequence of more complex cellular mechanisms (i.e., alteration of receptor subcellular localization, and signaling / trafficking kinetics). Many of the methodologies currently used to study RTK activation and screen for therapeutics revolve around RTK kinase activity. The development of tools providing new insight into these complex mechanisms is crucial to better understand RTK biology and to develop more effective RTK-targeting drugs. In this GEN webinar, our expert panelists will introduce bioSensAll™, an enhanced bystander bioluminescence resonance energy transfer (ebBRET)-based biosensor technology and its applications to interrogate RTK biology and expand current RTK drug discovery efforts. This new technology offers a new pluridimensional view of RTK signaling, enabling advancements in RTK-targeting drug discovery.
- Share your Experience